Bincy P. Abraham, MD

Fondren Distinguished Professor in Inflammatory Bowel Disease, Department of Medicine
Associate Professor of Clinical Medicine, Institute for Academic Medicine
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Bincy P. Abraham, MD, MS, is an associate professor of clinical medicine in the Academic Division of Gastroenterology and Hepatology at Houston Methodist – Weill Cornell in Houston, Texas.

Dr. Abraham earned her undergraduate degree in bioengineering at Texas A&M University in College Station, and then received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston. She completed her internal medicine internship and residency, as well as a gastroenterology fellowship at UTMB, where she also earned a master’s in clinical investigation and received specialized training in inflammatory bowel disease (IBD). During her training, she completed a National Visiting Fellow IBD Rotation Program through the Crohn’s and Colitis Foundation of America at Cedars-Sinai Medical Center in Los Angeles, California. She is board certified in Internal medicine and Gastroenterology. Dr. Abraham is a member of the American Gastroenterological Association, American College of Gastroenterology, Crohn’s and Colitis Foundation, American Society of Gastrointestinal Endoscopy, and chair of the South Texas Chapter of the Crohn’s and Colitis Foundation Medical Advisory Committee.

Description of Research

Dr. Abraham is a principal investigator and coinvestigator in several key clinical trials. As author or coauthor, Dr. Abraham’s work has been published in peer-reviewed medical journals including Clinical Gastroenterology and Hepatology, American Journal of Gastroenterology, and Inflammatory Bowel Diseases.

Areas Of Expertise

Capsule endoscopy Ulcerative colitis Pregnancy & inflammatory bowel disease Transition of care in inflammatory bowel disease Crohn's disease
Active Clinical Trials






A Probiotic for Ulcerative Colitis: The Culture Wars Continue
Abraham, BP & Quigley, EMM 2018, Digestive Diseases and Sciences, pp. 1-3. DOI: 10.1007/s10620-018-5097-1

Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, pharmacokinetic study
Mariette, X, Förger, F, Abraham, B, Flynn, AD, Moltó, A, Flipo, RM, Van Tubergen, A, Shaughnessy, L, Simpson, J, Teil, M, Helmer, E, Wang, M & Chakravarty, EF 2018, Annals of the Rheumatic Diseases, vol. 77, no. 2, pp. 228-233. DOI: 10.1136/annrheumdis-2017-212196

Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases
Corbo, C, Cromer, WE, Molinaro, R, Toledano Furman, NE, Hartman, KA, De Rosa, E, Boada, C, Wang, X, Zawieja, DC, Agostini, M, Salvatore, F, Abraham, BP & Tasciotti, E 2017, Nanoscale. DOI: 10.1039/c7nr04734g

Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease among Patients with Inflammatory Bowel Disease
Glassner, K, Malaty, HM & Abraham, BP 2017, Inflammatory Bowel Diseases, vol. 23, no. 6, pp. 998-1003. DOI: 10.1097/MIB.0000000000001085

Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease
Sandborn, WJ, Wolf, DC, Kosutic, G, Parker, G, Schreiber, S, Lee, SD, Abraham, B, Afzali, A, Arsenescu, RI, Gutierrez, A, Spearman, M, Coarse, J & Feagan, BG 2017, Inflammatory Bowel Diseases, vol. 23, no. 7, pp. 1047-1056. DOI: 10.1097/MIB.0000000000001100

Polymorphisms of 5-HTT LPR and GNß3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial
Saito, YA, Locke, GR, Almazar, AE, Bouras, EP, Howden, CW, Lacy, BE, DiBaise, JK, Prather, CM, Abraham, BP, El-Serag, HB, Moayyedi, P, Herrick, LM, Szarka, LA, Camilleri, M, Hamilton, FA, Schleck, CD, Tilkes, KE, Zinsmeister, AR & Talley, NJ 2017, American Journal of Gastroenterology. DOI: 10.1038/ajg.2017.52

Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches
Abraham, BP, Ahmed, T & Ali, T 2017, . in B Greenwood-Van Meerveld (ed.), Gastrointestinal Pharmacology. vol. 239, Handbook of Experimental Pharmacology, vol. 239, Springer, pp. 115-146. DOI: 10.1007/164_2016_122

Probiotics in Inflammatory Bowel Disease
Abraham, BP & Quigley, EMM 2017, Gastroenterology Clinics of North America. DOI: 10.1016/j.gtc.2017.08.003

Cancer surveillance in ulcerative colitis and Crohn's disease: New strategies
Abraham, BP 2016, Current Opinion in Gastroenterology, vol. 32, no. 1, pp. 32-7. DOI: 10.1097/MOG.0000000000000234

The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease
Koduru, P & Abraham, BP 2016, Therapeutic Advances in Gastroenterology, vol. 9, no. 1, pp. 76-85. DOI: 10.1177/1756283X15616577

Symptom management in inflammatory bowel disease
Abraham, BP 2015, Expert Review of Gastroenterology and Hepatology, vol. 9, no. 7, pp. 953-967. DOI: 10.1586/17474124.2015.1038241

Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study
Melmed, GY, Pandak, WM, Casey, K, Abraham, B, Valentine, J, Schwartz, D, Awais, D, Bassan, I, Lichtiger, S, Sands, B, Hanauer, S, Richards, R, Oikonomou, I, Parekh, N, Targan, S, Johnson, K, Hariri, R & Fischkoff, S 2015, Inflammatory Bowel Diseases, vol. 21, no. 8, pp. 1809-16. DOI: 10.1097/MIB.0000000000000441

Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: Analyses from the 7-year PRECiSE 3 study
Sandborn, WJ, Melmed, GY, McGovern, DPB, Loftus, EV, Choi, JM, Cho, JH, Abraham, B, Gutierrez, A, Lichtenstein, G, Lee, SD, Randall, CW, Schwartz, DA, Regueiro, M, Siegel, CA, Spearman, M, Kosutic, G, Pierre-Louis, B, Coarse, J & Schreiber, S 2015, Alimentary Pharmacology and Therapeutics, vol. 42, no. 3, pp. 330-342. DOI: 10.1111/apt.13251

Effect of amitriptyline and escitalopram on functional dyspepsia: A multicenter, randomized controlled study
Talley, NJ, Richard Locke, G, Saito, YA, Almazar, AE, Bouras, EP, Howden, CW, Lacy, BE, Dibaise, JK, Prather, CM, Abraham, BP, El-Serag, HB, Moayyedi, P, Herrick, LM, Szarka, LA, Camilleri, M, Hamilton, FA, Schleck, CD, Tilkes, KE & Zinsmeister, AR 2015, Gastroenterology, vol. 149, no. 2, pp. 340-349.e2. DOI: 10.1053/j.gastro.2015.04.020

Medical and Surgical Complications of Inflammatory Bowel Disease in the Elderly: A Systematic Review
Shung, DL, Abraham, B, Sellin, J & Hou, JK 2015, Digestive Diseases and Sciences, vol. 60, no. 5, pp. 1132-1140. DOI: 10.1007/s10620-014-3462-2

MicroRNA signatures differentiate Crohn's disease from ulcerative colitis
Schaefer, JS, Attumi, T, Opekun, AR, Abraham, B, Hou, J, Shelby, H, Graham, DY, Streckfus, C & Klein, JR 2015, BMC Immunology, vol. 16, no. 1, 69. DOI: 10.1186/s12865-015-0069-0

Frequency and associated factors of hair loss among patients with inflammatory bowel disease
Shah, R, Abraham, B, Hou, J & Sellin, J 2015, World Journal of Gastroenterology, vol. 21, no. 1, pp. 229-232. DOI: 10.3748/wjg.v21.i1.229

Transition of care in inflammatory bowel disease
Abraham, BP & Kahn, SA 2014, Gastroenterology and Hepatology, vol. 10, no. 10, pp. 633-640.

Fecal calprotectin: Controlling the cost of care
Abraham, BP & Sellin, JH 2014, Clinical Gastroenterology and Hepatology, vol. 12, no. 2, pp. 263-264. DOI: 10.1016/j.cgh.2013.09.018

Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients
Abraham, BP, Prasad, P & Malaty, HM 2014, Digestive Diseases and Sciences, vol. 59, no. 8, pp. 1878-1884. DOI: 10.1007/s10620-014-3102-x